Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective

Overview of attention for article published in Frontiers in oncology, March 2023

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 11 Mendeley

So far, Altmetric has seen 1 X post from an account with 6,555 followers.

New research: Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective: Aim To evaluate the cost-effectiveness of palbociclib plus… https://t.co/qFzm

22 Mar 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.